GlassScriptPhysician profile
Parvati Daram Ananthula
NPI 1669475448
$3,361.60
in general payments reported to CMS, 2019-2025
40 companies · $723 in 2025
The $723 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $206 · 2021: $334 · 2022: $453 · 2023: $657 · 2024: $713 · 2025: $723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,048 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,047.86 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $607.09 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $573.07 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $253.97 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $192.19 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $182.17 | 2022-2023 | |
| Lilly USA, LLC | $166.51 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Astellas Pharma US INC | $165.18 | 2019-2025 | Veozah |
| Lundbeck LLC | $144.06 | 2022-2025 | Vyepti |
| Novartis Pharmaceuticals Corporation | $107.66 | 2019-2023 | |
| Amgen INC. | $92.90 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $76.98 | 2019-2025 | Breztri |
| Actelion Pharmaceuticals US, INC. | $68.84 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.93 | 2020-2025 | Xifaxan |
| Dexcom, INC. | $56.99 | 2023-2024 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $47.39 | 2022-2024 | Camzyos, Eliquis |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parvati Ananthula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.